Libra – which is the name of Facebook (FB)’s upcoming cryptocurrency- has already managed to cause quite a stir among bankers and politicians across the world. Along with the present difficulties with the regulations and the consequences it would bring, the currency is now also dealing with opposition and cautions from international communities. Needless to say that this move has also boosted tech stocks related to cryptocurrency as well
Policymakers Worldwide Speak Against The Crypto-Currency
France was one of the many countries to resist making Libra a sovereign currency. Bruno Le Maire, the Finance Minister of the nation protested vehemently against Libra, claiming that the idea of a private company becoming a state doesn’t sit well. The country further is levying a new tax on the technology giants like Amazon pay, Google, etc which has caused some controversy. Even Jerome Powell, the Chairman of Federal Reserve disputed against the cryptocurrency being anxious about privacy and consumer protection.
Mark Carney, the Governor of Bank of England, also spoke against Libra claiming that it could either succeed or fail, but it would have no scope for improvement and development once it is launched. If successful, it would definitely prove to be a great asset; however, there can be no guarantee that it would be rock solid from the very beginning without which it is bound to fail. These types of scope around currencies demand strict and definite vigorous regulations to be set. The hurdles seem to be big enough to delay the launch of Libra into the market- which has been scheduled for next year.
Tech Giants Ban Together For Crypto?
Uber, Mastercard, Visa, and Facebook came together as an association to oversee the launch of Libra. This is a cryptocurrency different from bitcoin which is aimed to have a stable value without any volatility. It would help the World Bank-claimed 1.7 billion adults to have access to financial institutions and banking services. At the same time, it could help Facebook make big money through its app wallet -Calibra.
Facebook’s executive David Marcus maintained that the company knows of the risks that Libra might pose if proved unsuccessful. Therefore the company requested the help of bankers, lawmakers, and regulators so as to do away with issues of money laundering, terrorist financing, etc.
Roscan (ROS.V) Expands Gold Zone at Mankouke and Makes a New Discovery at Its Kandiole Project in Western Mali
Bedford, Nova Scotia–(Newsfile Corp. – July 22, 2019) – Roscan Gold Corporation (TSXV: ROS) (“Roscan” or the “Company”) is pleased to announce the positive assay results from both its diamond drilling and air core (AC) drilling programs at its Kandiole Project in Mali, West Africa. This drilling program was completed during April to July of 2019 and was designed to test both the north and south extensions of the Mankouke gold discovery zone and many other strong termite and soil, gold anomalies.
The Mankouke gold discovery has been shown, by detailed drilling, to have a strike length of at least 500 metres. In addition, the recent very impressive AC drilling assay results at the southern end of the Mankouke permit, as shown in Figure 1, supports the existence of a 7-kilometer long mineralization target corridor associated with the Mankouke discovery.
|In hole ACMan 19-167||5.86 g/t Au over 26.0 m (incl. 9.44 g/t Au over 10.0 m)|
|In hole ACMan 19-168||3.74 g/t Au over 30.0 m (incl. 6.73 g/t Au over 6.0 m)|
|In hole DDH 19-04||8.63 g/t Au over 10.0 m (incl. 11.48 g/t Au over 7.0 m)|
|In hole DDH 19-03||6.53 g/t Au over 5.0 m (incl. 10.09 g/t Au over 3.0 m)|
|In hole DDH 19-03||5.56 g/t Au over 3.0 m (incl. 7.14 g/t Au over 2.0 m)|
|In hole DDH 19-08||3.45 g/t Au over 10.0 m (incl. 6.76 g/t Au over 3.0 m)|
Note: True widths cannot be determined with the information available
A summary of all assay results is presented in Table 1.
Greg Isenor, President and CEO of Roscan Gold, stated: “We are continuing to show that we have an excellent new gold discovery at Mankouke that appears to have strike and depth continuity. Our land package has great potential and we are extremely encouraged by the hits we are seeing on the Mankouke permit. There are many assays yet to be received and these will be available in the coming weeks. We are extremely pleased our approach to exploration in this area has been successful. Additional drilling is part of an obvious next step.
The drilling around the Mankouke discovery shows that a strong mineralization system exists and is” alive”. This is not supergene mineralization. We have drilled 19 core holes and have received results for 11 and have significant assays in 8 of the 11 holes. We are waiting for results for both AC and DDH on the north extension of the trend. (See fig 2). Deeper holes are planned when we return to drilling after the rain season. The drilling season is over for a few months, however many results yet to be received. We have the funds to continue drilling after the seasonal rains (July to October). In addition, the excellent AC results we received in the south of the Mankouke permit (see fig 1) will be followed up as soon as possible.“
The drilling was carried out during the period May to July with two rigs, one air core drilling rig and one multi-purpose diamond drilling rig. The diamond drilling was completed in the Mankouke discovery zone area and designed to test for extensions to the zone. The drilling program has been suspended until the end of the rainy season. At this point in the drilling program, there has been 19 diamond drill holes completed for a total of 2,017 meters. Assay results have not been received for eight diamond drill holes. See Figure 2.
A total of 607 AC holes were drilled for a total meterage of 28,037 metres. Approximately 60% of the assays of the AC drilling have been received. The AC drilling covered the entire land package with testing the most important termite anomalies. Lines of AC holes were drilled across the target areas generally in an east-west direction and drilled at -50 degrees to the west to a depth of 45 to 60 metres in a heel to toe fashion. AC drilling is used to sample unconsolidated ground with compressed air used to remove the cuttings from the hole. During the Kandiole drilling program, 2 metres long samples were collected. For each 2 metre intersection an ~2-kilogram sample was collected and sent to the laboratory. A check sample of approximately 5 kilograms was collected for possible future tests.
The gold mineralization intersected to date in the Mankouke Zone is hosted in breccia zones which are interbedded with saprolitic metasediments. Recent core holes have intersected gold mineralized breccia (8.63 g/t Au over 10 metres from 79.1 metres to 89.1 metres along the drill hole) at a vertical depth of 60 metres. This drilling indicates that the initially reported gold discovery (News Release January 24, 2019) has “roots” and is not near surface enrichment (supergene). This drilling information clearly shows the potential at depth in this area and identifies that this is typical Birimian, hydrothermal-type gold mineralization.
Additional interpretation will be completed when all data is available.
Remaining assays will be received and processed during the rainy season. It is expected that drilling will resume as early as mid-October and will primarily consist of both diamond drilling, to test for both the extensions of the Mankouke gold discovery, and, to test significant AC intersections identified in other areas of the property. In addition, AC drilling will be continued to test the remaining, untested termite and gold soil anomalies.
QUALIFIED PERSON AND SAMPLE PROTOCOL
The technical content in this news release has been reviewed and approved by Gregory P. Isenor, P. Geo, a Qualified Person as defined by NI 43-101.
For quality control, duplicated samples were systematically collected in the field, and blank samples were inserted in the sample batches sent to the laboratory. Before their transportation, the samples were stored in a Roscan secured location in the field. Batches of samples were transported by truck, driven by Roscan contractors, to the Bureau Veritas laboratory sample preparation installation of in Bamako; prepared samples were then shipped by Bureau Veritas to their treatment installation at Abidjan, Ivory Coast. During the assay process, the laboratory applied its own quality controls with blanks, duplicates and standard samples. The assay method was atomic absorption (AA) with pre-concentration by fire assay (FA); the detection limit of the method is of 5 ppb.
Roscan Gold Corporation is a Canadian gold exploration company focused on the acquisition and exploration of gold properties in West Africa. The Company has assembled a significant land position of 100%-owned permits in an area of producing gold mines (including B2 Gold’s Fekola Mine which lies in a contiguous property to the west of Kandiole), and major gold deposits, located both north and south of its Kandiole Project in west Mali.
For further information, please contact:
President and Chief Executive Officer
Tel: (902) 832-5555
Forward Looking Statements
This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information is characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, changes in the state of equity and debt markets, fluctuations in commodity prices, delays in obtaining required regulatory or governmental approvals, and other risks involved in the mineral exploration and development industry, including those risks set out in the Company’s management’s discussion and analysis as filed under the Company’s profile at www.sedar.com. Forward-looking information in this news release is based on the opinions and assumptions of management considered reasonable as of the date hereof, including that all necessary governmental and regulatory approvals will be received as and when expected. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information. The Company disclaims any intention or obligation to update or revise any forward-looking information, other than as required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SIGNIFICANT ASSAY RESULTS
AIR CORE DRILLING PROGAM 2019
|Hole #||Line #||FROM|
|ACKaN-19-06||S 1383715 N||2.0|
|0.68 g/t Au over 2.0 m|
1.05 g/t Au over 2.0 m
0.71 g/t Au over 2.0 m
0.72 g/t Au over 2.0 m
|ACMan-19-47||S 1379900 N||30.0||32.0||0.56 g/t Au over 2.0 m|
|ACMan-19-48||S 1379900 N||12.0||14.0||0.62 g/t Au over 2.0 m|
|ACMan-19-49||S 1379900 N||16.0||22.0||0.49 g/t Au over 6.0 m|
|ACMan-19-51||S 1379900 N||2.0|
|1.92 g/t Au over 2.0 m|
1.46 g/t Au over 6.0 m
1.34 g/t Au over 2.0 m
|ACMan-19-74||S 1382160 N||34.0||36.0||0.51 g/t Au over 2.0 m|
|ACMan-19-84||S 1380600 N||30.0|
|1.24 g/t Au over 10.0 m|
0.53 g/t Au over 2.0 m
|ACMan-19-85||S 1380600 N||38.0||44.0||2.44 g/t Au over 6.0 m|
|ACMan-19-86||S 1380600 N||12.0|
|3.10 g/t Au over 2.0 m|
4.29 g/t Au over 4.0 m
|ACMan-19-88||S 1380650 N||14.0||16.0||3.75 g/t Au over 2.0 m|
|ACMan-19-89||S 1380650 N||42.0||44.0||0.79 g/t Au over 2.0 m|
|ACMan-19-90||S 1380650 N||16.0||18.0||2.18 g/t Au over 2.0 m|
|ACMan-19-155||S 1382350 N||18.0||20.0||2.15 g/t Au over 2.0 m|
|ACMan-19-163||S 1375850 N||36.0||42.0||1.24 g/t Au over 6.0 m|
|ACMan-19-165||S 1375850 N||6.0|
|0.91 g/t Au over 4.0 m|
2.37 g/t Au over 2.0 m
|ACMan-19-166||S 1375850 N||6.0|
|1.40 g/t Au over 18.0 m|
8.14 g/t Au over 4.0 m
6.13 g/t Au over 6.0 m
|ACMan-19-167||S 1375850 N||4.0|
|4.50 g/t Au over 16.0 m|
Inc. 23.00 g/t Au over 2.0 m
5.86 g/t Au over 26.0 m
Inc. 10.20 g/t Au over 2.0 m
Inc. 9.44 g/t Au over 10.0 m
|ACMan-19-168||S 1375850 N||4.0|
|3.00 g/t Au over 10.0 m|
Inc. 10.60 g/t Au over 2.0 m
3.74 g/t Au over 30.0 m
Inc. 6.73 g/t Au over 6.0 m
Inc. 9.19 g/t Au over 4.0 m
|ACMan-19-169||S 1375850 N||0.0|
|0.54 g/t Au over 2.0 m|
1.34 g/t Au over 8.0 m
3.23 g/t Au over 12.0 m
Inc. 5.92 g/t Au over 4.0 m
|ACMan-19-170||S 1375850 N||10.0|
|2.76 g/t Au over 26.0 m|
Inc. 6.76 g/t Au over 2.0 m
Inc. 8.74 g/t Au over 4.0 m
|ACMan-19-171||S 1375850 N||6.0||8.0||0.64 g/t Au over 2.0 m|
|ACMan-19-181||S 1377200 N||4.0||6.0||1.31 g/t Au over 2.0 m|
|ACMan-19-189||S 1377200 N||26.0||28.0||1.01 g/t Au over 2.0 m|
|ACMan-19-196||S 1377200 N||4.0||6.0||1.59 g/t Au over 2.0 m|
|ACMan-19-200||S 1377420 N||22.0||24.0||2.10 g/t Au over 2.0 m|
|ACMan-19-217||S 1377420 N||6.0|
|1.00 g/t Au over 6.0 m|
0.99 g/t Au over 2.0 m
|ACMan-19-229||S 1378200 N||24.0||26.0||0.65 g/t Au over 2.0 m|
|ACMou-19-01||S 1398350 N||0.0||2.0||1.33 g/t Au over 2.0 m|
|ACMou-19-03||S 1398350 N||12.0|
|0.81 g/t Au over 4.0 m|
0.54 g/t Au over 2.0 m
|ACMou-19-08||S 1398080 N||26.0||28.0||0.79 g/t Au over 2.0 m|
|ACMou-19-10||S 1397290 N||6.0|
|0.52 g/t Au over 2.0 m|
3.82 g/t Au over 6.0 m
Inc. 8.46 g/t Au over 2.0 m
|ACNia-19-04||S 1380260 N||20.0||22.0||0.64 g/t Au over 2.0 m|
Note 1: This table includes all the mineralized intersections with a grade > 0.50 g/t Au; these intersections are considered as significant intersections.
Note 2: Intersections in bold refer to intersections with a grade > 0.50 g/t Au, and a length > 2.0.
Note 3: True widths cannot be determined with the information available.
DIAMOND DRILLING PROGRAM 2019
|Hole #||Line #||FROM|
|1.04 g/t Au over 4.0 m|
1.97 g/t Au over 1.0 m
|DDHMan-19-02||1380500 N||75.1||77.1||0.99 g/t Au over 2.0 m|
|5.56 g/t Au over 3.0 m|
Inc. 7.14 g/t Au over 2.0 m
6.48 g/t Au over 2.0 m
Inc. 8.98 g/t Au over 1.0 m
6.53 g/t Au over 5.0 m
Inc. 10.09 g/t Au over 3.0 m
2.60 g/t Au over 0.9 m
|1.69 g/t Au over 1.0 m|
0.80 g/t Au over 4.0 m
8.63 g/t Au over 10.0 m
Inc. 11.48 g/t Au over 7.0 m
|1.30 g/t Au over 1.0 m|
0.73 g/t Au over 1.0 m
|0.71 g/t Au over 1.0 m|
14.88 g/t Au over 1.6 m
Inc. 34.00 g/t Au over 0.6 m
0.58 g/t Au over 1.0 m
|1.07 g/t Au over 1.0 m|
12.70 g/t Au over 1.0 m
3.45 g/t Au over 10.0 m
Inc. 6.76 g/t Au over 3.0 m
6.29 g/t Au over 1.0 m
|DDHMan-19-12||1380600 N||104.0||105.0||1.07 g/t Au over 1.0 m|
|0.75 g/t Au over 1.0 m|
1.10 g/t Au over 1.0 m
0.64 g/t Au over 1.0 m
4.16 g/t Au over 2.0 m
Inc. 7.81 g/t Au over 1.0 m
0.56 g/t Au over 1.0 m
1.51 g/t Au over 1.0 m
Note 1: This table includes all the mineralized intersections with a grade > 0.50 g/t Au; these intersections are considered as significant intersections.
Note 2: Intersections in bold refer to intersections with a grade > 0.50 g/t Au, and a length > 2.0.
Note 3: True widths cannot be determined with the information available.Cannot view this image? Visit: https://media.zenfs.com/en-us/newsfile_64/ea5917b2bb71d8cd5cb3d04eb3e0b297More
To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/4821/46368_b01c8377e4b94ae8_001full.jpgCannot view this image? Visit: https://media.zenfs.com/en-us/newsfile_64/35ccfc69eef57cdc1b5b20a061166663More
To view an enhanced version of Figure 2, please visit:
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/46368
Netflix (NFLX) Stock Price Falls After Lower Subs; What Next For Tech Stocks?
The streaming leader, Netflix (NFLX) seems to have taken a hit where the subscriber additions are considered. This would be the second time over the last nine quarters that the company has failed to miss on the additions of subscribers by a massive figure of 2.3 million.
Netflix reported for its previous quarter an increase in its revenue by 26% along with an EPS of $0.60. Yet the US subscribers saw a decline by 130,000. Combined with the company’s low profitability and negative cash flows, the stocks of the company may seem to be overvalued. But considering the spending that is being done across the tech sector, this decline may appear a more short term issue. This being said, other technology stocks have been increasing corporate footprints of their own.
Tech Stocks That Could Benefit From The Boom In New Streaming Stocks
The “Netflix and Chill” mentality of the new generation of viewers may have created an opportunity for certain niche sectors. One of these niche’s is on-demand delivery stocks. Amazon and Uber have entered the space with a significant focus on timeliness. However, as Uber puts it, UberEats may be the loss leader for the company due to the infrastructure. Furthermore, Amazon may be more insulated due to the sheer size of its core business.
This being said, it’s vital to look at companies that may be smaller, more nimble, and streamlined for potential profitability. In this regard, ParcelPal (PTNYF) (PKG) has been a company that we’ve discussed numerous times in the past. The company targets on-demand delivery of pretty much anything. But what has set it apart from the UberEats and Postmates of the world is their direct integration of cannabis.
Something that is beginning to set ParcelPal (PTNYF) (PKG) apart from its immediate competition is its diversification strategy. Not only is the company working with the likes of Amazon, but it is also entering into key verticals that are seeing an increase in rapid demand. Right now, ParcelPal (PTNYF) (PKG) has built relationships with businesses in both alcohol and cannabis.
We don’t have to go into the deep details of these booming industries, but it is vital to understand that the evolution from brick-and-mortar to on-demand delivery could be setting the stage for a major economic boom.
While consumers are becoming more comfortable with using smartphones and computers to buy groceries, they are also increasingly using the same technology to help them skip trips to the liquor store, according to data from the e-commerce analytics firm, Slice Intelligence. Netflix and Chill just got an upgrade!
What Does The Future Of Netflix Hold?
Market saturation has become quite a concern for investors. With the current 60.1 million subscribers as compared to the year-ago quarter figure of 55.7 million, it sure is an improvement. However, as per the targets of 60 million to 90 million, as claimed by the company’s CEO Reed Hastings, Netflix barely managed to reach the lower range.
In May, the company implemented a price rise by 18% from US$10.99 to US$12.99 and did not lose much of its customers which is an impressive feat. What also needs to keep in mind is that the previous quarter was relatively light. This is even with blockbuster shows like Stranger Things dropping towards the end of the quarter.
Bigger Costs Could Be Coming; Lower Netflix Stock Price To Follow?
The company also has huge marketing costs it plans to undertake in the later part of 2019. If history serves right then it could bring in enormous subscribers. Previous quarter had seen only a slight increase than a year ago in the marketing expenditure. As compared to quarter including March, the marketing spends actually went down by $13 million.
Among other worries, content leaving the platform and the rising competition has left the investors anxious. Netflix is losing its most-watched show “The Office” to Comcast. In addition, its second most-watched “Friends” is lost to AT&T. This is happening all while Disney will be taking back its movies – all of which would happen after next year. However, Disney, AT&T, and Comcast are yet to announce their own upcoming streaming services.
It may make it unlikely that consumers are shifting to these platforms. The miss on subscriber additions could be credited to the steep 18% price increase by the company. The light content and marketing also played its part in subscriber additions. The future does not actually seem bleak for the company.
PharmaCyte Biotech (PMCB) and UTS Creating Advanced Version of Melligen Cells to Treat Diabetes
PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced it has entered into a new research agreement with the University of Technology Sydney (UTS) in Australia to create a new version of Melligen cells for the treatment of diabetes with the potential to express higher levels of insulin.
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are pleased to have come to an agreement with UTS that allows us to take the Melligen cells to the next level in our development of a ‘bioartificial pancreas’ for the treatment of Type 1 and insulin-dependent Type 2 diabetes. If we are successful, it will bring to fruition the many years of research that have been conducted by Professor Ann Simpson and her colleagues at UTS as well as PharmaCyte in developing these remarkable insulin-producing cells.”
Melligen cells are human liver cells that have been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the body. PharmaCyte has obtained the exclusive worldwide license rights from UTS to use these cells to develop a therapy for Type 1 and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate Melligen cells using the Cell-in-a-Box® technology to protect the Melligen cells from immune system attack in the body and thus function as a “bioartificial pancreas” for purposes of insulin production.
The work undertaken by PharmaCyte, UTS and PharmaCyte’s International Diabetes Consortium over the last two years has resulted in an opportunity to re-engineer the Melligen cells with the aim of increasing their insulin production as well as the bioactivity of the produced insulin. With this new agreement in place, the research will be done in Australia under the leadership of Prof. Ann Simpson, the developer of the original Melligen cell line.
The unique properties that set the Melligen cells apart from all other available insulin-producing cell types, include their robustness, their ability to withstand an attack from cell-toxic molecules that typically lead to the destruction of insulin-producing cells and their suitability for cost-efficient pharmacological-grade large scale production. In contrast to primary beta islet cells of the pancreas, which normally produce insulin and stem-cell-derived insulin producing cells, Melligen cells are a scalable and a highly characterized cell line that can readily be expanded in a bioreactor to generate the amounts of cells needed for cell banking, testing and production.
Professor Simpson commented, “We are extremely pleased that we have come to an agreement with PharmaCyte to continue our work on the Melligen cells and advance them to their full potential. Both UTS and PharmaCyte are investing in this important research because we believe in the significant health impact potential. This takes us a step closer to eliminating the need for diabetics to inject insulin daily and, more importantly, protects them from developing the debilitating complications of the disease such as blindness, neuropathy and possible amputations, kidney failure and cardiovascular problems. We look forward to working with PharmaCyte and its International Diabetes Consortium to improve the Melligen cells and to utilize them with the Cell-in-a-Box®encapsulation technology to create a potential cure for diabetes.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.
PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and beta islet cells. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.
International Diabetes Consortium
PharmaCyte Biotech has established an International Diabetes Consortium (Diabetes Consortium) that consists of world-renowned physicians and scientists from several countries, all of whom share the same goal of developing a treatment for Type 1 and insulin-dependent Type 2 diabetes.
In addition to the Chief Executive Officer, Chief Operating Officer, Chief Scientific Officer and Chief Medical Officer of PharmaCyte, the Diabetes Consortium is made up of well-known physicians and scientists from leading Universities in Munich, Germany, Mannheim, Germany, Vienna, Austria, Barcelona, Spain, Copenhagen, Denmark, and Sydney, Australia. It also involves members from the Karolinska Institute in Stockholm, Sweden, the Vorarlberg Institute for Vascular Investigation and Treatment in Feldkirch, Austria and the biotech company Austrianova in Singapore.
Dr. Eva Maria Brandtner leads the Consortium and is PharmaCyte’s Director of Diabetes Program Development. Dr. Brandtner, who is a consultant for PharmaCyte, previously served as the Chief Scientist with Austrianova. In that role, she conducted preclinical studies with the Melligen cells. Prof. Ann. M Simpson and her colleagues at the University of Technology Sydney developed the Melligen cells. Prof. Simpson is a member of the Consortium.
In addition to key personnel from PharmaCyte, Dr. Brandtner and Prof. Simpson, the Diabetes Consortium includes Prof. Dr. Walter H. Günzburg, the Chief Scientific Officer of PharmaCyte Biotech and the Chief Technical Officer of Austrianova, and Dr. Brian Salmons, the Chief Executive Officer of Austrianova and a member of PharmaCyte’s Medical and Scientific Advisory Board. It also includes research scientists Prof. Dr. Eckhard Wolf and Prof. Dr. Rüdiger Wanke from the Ludwig-Maximillian University (LMU) in Munich, Germany. Both, together with their colleagues at LMU, have developed unique animal models for insulin-dependent diabetes. Other key members of the Diabetes Consortium include Prof. Dr. Hans-Peter Hammes, Professor of Internal Medicine and Endocrinology, Faculty of Clinical Medicine Mannheim of Heidelberg University and Section Leader for Endocrinology and Diabetology, Mannheim, Germany, Prof. Dr. Thomas Stratman of the University of Barcelona in Spain and Prof. Dr. Axel Kornerup Hanson of the University of Copenhagen in Denmark.
About University of Technology Sydney
UTS is a dynamic and innovative university in central Sydney. One of Australia’s leading universities of technology, UTS has a distinct model of learning, strong research performance and a leading reputation for engagement with industry and the professions. Based in the vibrant creative and start-up precinct in Ultimo, it has more than 40,000 students and is rated No.1 ‘young’ university in Australia in both the QS and Times Higher Education rankings.
More information about UTS can be found at www.uts.edu .au.
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the United States Securities and Exchange Commission.
More information about PharmaCyte can be found at www.PharmaCyte .com. It can also be obtained by contacting Investor Relations.
Contact:Dr. Gerald W. Crabtree
PharmaCyte Biotech, Inc.
Investor Relations Department
Email: Info@PharmaCyte. com
Search Stock Price (StockPrice.com)
Sponsored Content1 month ago
Special Delivery! On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market
Featured4 months ago
Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond
Cannabis3 months ago
Two Massive Growth Industries, One Choice for Investors
Biotechnology2 months ago
Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks
Featured1 month ago
This New Technology Could Transform A Multi-Billion-Dollar Industry!
Cannabis2 months ago
A New Cannabis Trend That The Market Should Take Immediate Notice Of Is Here!
Biotechnology2 weeks ago
The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company
Featured4 months ago
Opportunity Ahead for This Healthcare Stock